Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
34058070 (PubMed )
Supplement: MOL2-15-2363-s001.docx
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Ducker GS et al.
Oncogene, 2014
PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.
Yu J et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2013
Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
Yip PY et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F et al.
Oncotarget, 2012
Select a paper to view details